CELL INTELLIGENCE · 肿瘤细胞治疗研究

Pancreatic ductal adenocarcinoma (PDAC) typically exhibits asymptomatic clinical features, with most patients diagnosed at an advanced metastatic stage. Current treatment options are limited to cytotoxic standard therapies, primarily FOLFIRINOX or modified FOLFIRINOX regimens. This highlights a critical need for targeted therapies to improve efficacy and reduce toxicity. We have sought to identify potential biomarkers based on DNA methylation profiles to identify patient groupings with improved overall survival (OS) based on the Transforming Growth Factor Beta (TGFB) gene complex, and the interferon-related pathway gene, IFI27 , using the TCGA dataset for PDAC patients. We employed a multivariate Cox proportional hazards model to directly compare hazard ratios for TGFB1/2/3 and IFI27 methylation impacting OS. We also controlled for age at diagnosis, sex, and TGFB2 gene methylation by examining the statistical interactions between the marker gene mRNA expression and the TGFB2 gene. Genes were filtered based on the tumor-specific expression patterns and Cox models with highly significant interaction terms to identify mRNA expression of genes that amplified the impact of TGFB2 methylation. The effect of the TGFB2 gene methylation in the context of marker gene mRNA expression was analyzed using Kaplan-Meier (KM) analysis. Marker genes were correlated to T-cell enrichment patterns using the deconvolution algorithms provided by the TIMER 2.0 database. Methylation of TGFB2 , TGFB3 and IFI27 genes using median cut-off values for KM plots showed significant improvements in median overall survival of 5.7 ( p = 0.044), 5.2 ( p = 0.036), and 3.7 ( p = 0.028) months for high methylation levels for TGFB2 , IFI27 , and TGFB3 genes, respectively. In contrast, high levels of TGFB1 methylation exhibited a shorter 4.7 ( p = 0.016) month median OS time. The impact of TGFB2 methylation was amplified at low expressions of marker genes that were highly correlated with CD8 + T-cell infiltration. Patients with high levels of TGFB2 methylation when compared to low levels of TGFB2 methylation showed median overall survival (OS) improvements at low mRNA expression levels: 54.2 months for CD3D ( p < 0.0001); 54 months for LCK ( p = 0.0009); 54.9 months for HLA-DRA ( p = 0.0001); and 9 months for RAC2 mRNA expression ( p = 0.0057). TGFB2 gene methylation drives TGFB2 mRNA expression to achieve clinical impact, as high levels of TGFB2 mRNA, at low levels of the marker genes, resulted in worse median OS times. TGFB2 methylation is a prognostic marker for PDAC patients within an immunosuppressed tumor microenvironment characterized by low CD8 + T-cell infiltration. This correlation is functionally associated with TGFB2 mRNA production, suggesting that targeting TGFB2 mRNA through knockdown can potentially enhance PDAC prognosis.